Artiva 2025 Q3 Earnings Narrowed EPS Loss, Wider Net Loss Amid Clinical Progress

Artiva (ARTV) reported its fiscal 2025 Q3 earnings on Nov 12, 2025, with mixed results. While the company narrowed its per-share loss by 4.3%, its net loss widened by 23.2% to $21.53 million. The report coincided with positive clinical updates for its AlloNK therapy and a surge in stock price activity.

Revenue

Total revenue remained stable at $0 in Q3 2025 compared to Q3 2024, reflecting the company’s current development-stage operations.

Earnings/Net Income

Artiva reduced its per-share loss to $0.88 from $0.92 in the prior year, a 4.3% improvement. However, the net loss expanded to $21.53 million, up 23.2% from $17.47 million in 2024 Q3. The company has posted losses for four consecutive years in the quarter, underscoring ongoing financial challenges. The EPS improvement is positive, but the widening net loss raises concerns.

Price Action

The stock price surged 10.86% on the latest trading day, 15.70% for the week, and 45.26% month-to-date, reflecting strong investor sentiment.

Post-Earnings Price Action Review

A strategy of purchasing ARTV shares on quarterly earnings report dates and holding for 30 days yielded a 24.71% return over three years. This approach leverages market optimism about the company’s financial trajectory, with the 30-day holding period capturing short-term price momentum driven by earnings announcements. The strategy’s profitability highlights the stock’s volatility and investor confidence in its long-term potential despite recurring losses.

CEO Commentary

Fred Aslan, CEO of Artiva Biotherapeutics, emphasized AlloNK’s potential to redefine B-cell depletion therapy for autoimmune diseases. He highlighted the regimen’s safety profile, with no severe side effects reported in 32 patients, and outlined plans for FDA interactions in 2026 to finalize pivotal trial design for refractory rheumatoid arthritis (RA).

Guidance

Artiva expects to share clinical response data from over 15 refractory RA patients in 1H 2026 and aims to initiate a global pivotal trial post-FDA alignment. The company projects sufficient cash reserves to fund operations through Q2 2027.

Additional News

1. FDA Fast Track Designation: AlloNK received Fast Track Designation for refractory RA, positioning it as the first therapy in the deep B-cell depletion category to achieve this regulatory milestone.

2. Positive Safety Data: Clinical trials confirmed no cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD) in 32 patients treated with AlloNK, with consistent B-cell depletion observed.

3. CFO Transition: Neha Krishnamohan will transition to an advisory role by year-end, with a search for her replacement underway.